论文部分内容阅读
医改定音,药企喜忧参半,“当然利好”或“并非利好”之声各有所异。无论如何,在执行力催促之下,药企也在未知中群策群力,蓄势待发。与此前“征求意见稿”出台后的混乱局面相比,如今的医药企业已稍显镇定。“当时简直跟炸了锅一样。”中国医药企业管理协会副秘书长牛正乾对记者说。2008年10月14日《医改征求意见稿》甫一出台,业内专家的看法不尽相同,矛盾的焦点集中在“建立健全药品供应保障体系”的相关规定上。医药企业更是集体上书,反对医改征求意见稿中以药品生产采购“统购统销”为代表的一系列政策。一时间,国家基本药物制度成为社会关注的焦点。如今,万众期盼之中的修改意见稿对此项规定做了很大的
Medical reform Tone, pharmaceutical companies mixed, “Of course good ” or “Not good ” Voice vary. In any case, under the urging of executive power, pharmaceutical companies are also in the unknown together, ready. Compared with the confusion after the introduction of the “Draft for Consultation,” the pharmaceutical companies of today have slightly calmed down. “At that time, it was almost the same as the pan.” Niu Zhenggan, deputy secretary general of China Association of Pharmaceutical Manufacturers told reporters. October 14, 2008 “Medical Reform Draft” was introduced as soon as possible, the views of industry experts are not the same, the focus of conflicts focused on the “establishment of a sound drug supply security system,” the relevant provisions. Pharmaceutical companies are more collective letters, opposition to medical reform draft for the purchase of drugs “purchase and marketing ” as the representative of a series of policies. For a time, the national essential drug system has become the focus of public concern. Today, the long-awaited amendment draft made a great deal of this provision